Psychiatric Dispatches Print Friendly  New Mechanisms of Action Explored in Promising Alzheimer’s Disease Therapies Two new therapies show promise targeting Alzheimer’s disease at little-explored mechanisms of action, researchers announced at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD). Such treatments may pave the way to safe and effective disease-modifying therapies for Alzheimer’s disease,…
Read >

  Latest Clinical Trial Data On Disease-Modifying Therapies from the 2008 International Conference on Alzheimer’s Disease Clinical trial results examining a diversity of promising Alzheimer’s disease therapies were presented at the 2008 Alzheimer’s Association International Conference on Alzheimer’s Disease in Chicago. The therapies presented targeted a wide variety of possible mechanisms of action and revealed…
Read >

Psychiatric Dispatches Print Friendly    Primary Psychiatry. 2008;15(8):21,24-26   Barriers Compromising Adherence to Positive Airway Pressure for Children with Obstructive Sleep Apnea Obstructive sleep apnea (OSA) is prevalent in 1% to 4% of the population. If untreated, it can lead to various ailments, including behavioral problems, neuropsychological deficits, and medical morbidity. Though there are effective…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2008;15(7):24-26 FDA Approves Duloxetine HCI for the Management of Fibromyalgia The United States Food and Drug Administration approved duloxetine HCI (Cymbalta, Eli Lilly) for the management of fibromyalgia. Fibromyalgia is estimated to affect 2% of the United States population, with the majority of diagnoses being made in women. Approval…
Read >

  First Annual Alzheimer’s Disease Summit Targeted Recent Advances in Diagnosis and Management Alzheimer’s disease (AD) is expected to increase dramatically in the coming decades as a consequence of global aging. In response to the growing public health need for recognition and optimal treatment of dementia and cognitive impairment associated with AD, leading experts in…
Read >

  FDA Approves Desvenlafaxine Succinate for Treatment of Major Depressive Disorder The United States Food and Drug Administration approved desvenlafaxine succinate (Pristiq, Wyeth Pharmaceuticals), a serotonin norepinephrine reuptake inhibitor, to treat adult patients with major depressive disorder (MDD). The recommended dosage for an adult with MDD is 50 mg/day. This dosage does not require titration,…
Read >

  FDA Approves Aripiprazole for Acute Treatment of Manic and Mixed Episodes in Pediatric Patients The United States Food and Drug Administration approved aripiprazole (Abilify, Bristol-Myers Squibb, Otsuka America Pharmaceuticals) for the acute treatment of manic and mixed episodes affiliated with bipolar I disorder with or without psychotic characteristics in adolescents between 10–17 years of…
Read >

  Inhibitory Endophenotypes Help Classify Schizophrenia and Bipolar Patients Clinicians often misdiagnose mania as schizophrenia while schizophrenia is usually mistaken for schizoaffective disorder. According to a study by Laura F. Martin, MD, of the University of Colorado, and colleagues, physiologic inhibitory endophenotypes may be able to differentiate patients with schizophrenia from patients with bipolar disorder.…
Read >

  Babies with Low Birth Weight More Prone to Future Depression and Anxiety An important chapter reopened in the controversial “nature versus nurture” debate, as a study by Ian Colman, PhD, at the University of Cambridge, and colleagues, suggests atypical neurodevelopment may lead to future profiles of depression and anxiety. The study involved data collected…
Read >

  FDA Approves Duloxetine for Maintenance Treatment of Major Depressive Disorder The United States Food and Drug Administration approved duloxetine (Cymbalta, Eli Lilly and Company) for the maintenance treatment of major depressive disorder (MDD) in adults ≥18 years of age. Duloxetine was previously approved for the acute treatment of MDD, management of diabetic peripheral neuropathic…
Read >

  FDA Approves Aripiprazole for the Treatment of Schizophrenia in Adolescents The United States Food and Drug Administration approved aripiprazole (Abilify, Bristol-Myers Squibb) for the treatment of schizophrenia in adolescents between 13 and 17 years of age. The recent approval for adolescents was based on a 6-week, double-blind study conducted at 101 centers in 13…
Read >

  This interview took place on October 25, 2007, and was conducted by Norman Sussman, MD.   This interview is also available as an audio PsychCastTM at http://psychcast.mblcommunications.com. Disclosure: Dr. Thase is consultant to AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, GlaxoSmithKline, Janssen, MedAvante, Neuronetics, Novartis, Organon, Sepracor, Shire US, Supernus, and Wyeth; is on…
Read >

  This interview took place on April 9, 2007, and was conducted by Norman Sussman, MD.   This interview is also available as an audio PsychCastTM at http://psychcast.mblcommunications.com. Disclosure: Dr. Marder is consultant to Bristol-Myers Squibb, Merck, Otsuka, Pfizer, Roche, sanofi-aventis, and Solvay.   Dr. Marder is professor at the Semel Institute of Neuroscience and…
Read >

  Levels of Active Brain Response to Facial-Expressed Emotion in Alcoholism Many social and physiologic factors can lead recovering alcoholics to relapse, including anxiety disorders, anger, and social pressure. According to a new study, the brains of alcoholics may have a significantly diminished ability to recognize and process certain emotions such as fear or disgust,…
Read >

  This interview took place on May 2, 2007, and was conducted by Norman Sussman, MD.   This interview is also available as an audio PsychCastTM at http://psychcast.mblcommunications.com. Disclosure: Dr. Wray receives grant support from the Australian National Health and Medical Research Council, the National Institutes of Health, and Sequenom, Inc.   Dr. Wray is…
Read >

  Suicide Attempts: Time Patterns Before and During Treatment The debate over the 2004 Food and Drug Administration black box warning on antidepressants is barely waning. Are suicide rates higher or lower for patients on antidepressants, regardless of age? Has the FDA warning prevented deaths by suicide or unintentionally caused more? The FDA warning specifically…
Read >

  This interview took place on April 16, 2007, and was conducted by Norman Sussman, MD.   This interview is also available as an audio PsychCastTM at http://psychcast.mblcommunications.com. Disclosure: Dr. Lieberman is a consultant to Eli Lilly and Pfizer; is on the advisory boards of AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Organon, and Pfizer; has a…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2007;14(8):16-18   SSRIs Associated With Lower Bone Density in the Elderly Approximately 62% of antidepressant prescriptions in the United States are for selective serotonin reuptake inhibitors (SSRIs), commonly used for the treatment of depression and often prescribed for the elderly. SSRIs inhibit a serotonin-transporting protein that may also be…
Read >

  Bullying in Middle Schools Bullying is a common occurrence in middle schools and affects both boys and girls alike. Bullies often have delinquency and aggression problems. Recent surveys suggest that 80% of middle school students view bullying as a problem. Students in 7th and 8th grade at five schools in California, Florida, Maryland, and…
Read >

  This interview took place on April 16, 2007, and was conducted by Norman Sussman, MD.   This interview is also available as an audio PsychCastTM at http://psychcast.mblcommunications.com. Disclosure: Dr. Regier oversees all federal- and industry-sponsored research and research training grants at the American Psychiatric Institute for Research and Education but receives no external salary…
Read >

Articles Print Friendly  Drug Abuse and Dependency Affects More Than 10% of Adults Although drug use, abuse, and dependence are prevalent in the United States population and are associated with substantial costs to individuals and society, epidemiologic data on prevalence, correlates, disability, treatment, and comorbidity are seldom reported. While drug abuse refers to the intense…
Read >

Articles Print Friendly  Inpatient Therapy Effective for Treatment-Resistant Obsessive-Compulsive Disorder in Adolescents Although cognitive-behavioral therapy (CBT) is the preferred treatment for obsessive-compulsive disorder (OCD) in adolescents, studies have shown that 37% of outpatients receiving CBT fail to show clinically significant improvement. In addition, there have been few studies evaluating the efficacy of inpatient CBT for…
Read >

Articles Print Friendly  Older At-Risk Adults Less Likely to Report Alcohol-Related Health Problems Prior research has shown that while older adults (≥55 years of age) consume alcohol in amounts comparable to younger adults, their demographic is four times as likely to meet diagnostic criteria for alcohol dependence, with 8% to 15% reporting that they use…
Read >

Articles Print Friendly  Serotonin Reuptake Inhibitors May be Associated with Increased Risk of Fracture in the Elderly In the United States, approximately 10% of elderly primary care patients suffer from major depressive disorder (MDD) and other depressive disorders. Selective serotonin reuptake inhibitors (SSRIs) are the preferred pharmacologic treatment for MDD as they are associated with…
Read >

Psychiatric Dispatches Print Friendly  Primary Psychiatry. 2007;14(2):17-18,20 FDA Approves Paliperidone for the Treatment of Schizophrenia The United States Food and Drug Administration approved paliperidone extended-release tablets (Invega, Janssen) for the treatment of schizophrenia. The recommended daily dose of paliperidone is 6 mg/day, administered in the morning, with a maximum daily dose of 12 mg/day. Approval…
Read >